Cited by 780HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsCancer Genomics and Diagnostics

The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Open access

Hyman, David M., Piha-Paul, Sarina A., Won, Helen, Rodon, Jordi, Saura, Cristina, Shapiro, Geoffrey I., Juric, Dejan, Quinn, David I., Moreno, Victor, Doger, Bernard, Mayer, Ingrid A., Boni, Valentina, Calvo, Emiliano, Loi, Sherene, Lockhart, Albert C., Erinjeri, Joseph P., Scaltriti, Maurizio, Ulaner, Gary A., Patel, Juber, Tang, Jiabin, Beer, Hannah, Selcuklu, S. Duygu, Hanrahan, Aphrothiti J., Bouvier, Nancy, Melcer, Myra, Murali, Rajmohan, Schram, Alison M., Smyth, Lillian M., Jhaveri, Komal, Li, Bob T., Drilon, Alexander, Harding, James J., Iyer, Gopa, Taylor, Barry S., Berger, Michael F., Cutler Jr, Richard E., Xu, Feng, Butturini, Anna, Eli, Lisa D., Mann, Grace, Farrell, Cynthia, Lalani, Alshad S., Bryce, Richard P., Arteaga, Carlos L., Meric-Bernstam, Funda, Baselga, José, Solit, David B.·2018·Nature

DOI 10.1038/nature25475PMC PMC5808581

Open this paper in CoChat — free account

Abstract

Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, 'basket' trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature25475

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citation
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,080
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777

Flagged first, then by citations

Show all 54 references

1 of the 54 references couldn’t be matched to a known paper.

Sorted by citations

Items 301–400 of 779

Biliary tract cancer prognostic and predictive genomics
Mondaca, S., Nervi, B., Pinto, M. P., & Abou‐Alfa, G. K. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.07.06 · Cited by 22
Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets
Lau, D. K., Mouradov, D., Wasenang, W., Luk, I. Y., Scott, C. M., Williams, D. S., Yeung, Y. H., Limpaiboon, T., Iatropoulos, G., Jenkins, L. J., et al. (2019) · iScience · doi:10.1016/j.isci.2019.10.044 · Cited by 23
HER3 Alterations in Cancer and Potential Clinical Implications
Kilroy, M. K., Park, S., Feroz, W., Patel, H., Mishra, R., Alanazi, S., & Garrett, J. T. (2022) · Cancers · doi:10.3390/cancers14246174 · Cited by 21
HER2-Positive Breast Cancer Treatment and Resistance
Veeraraghavan, J., Angelis, C. D., Gutiérrez, C., Liao, F.-T., Sabotta, C. M., Rimawi, M. F., Osborne, C. K., & Schiff, R. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_24 · Cited by 21
Tumour-agnostic kinase inhibitors
Adashek, J. J., Nikanjam, M., & Kurzrock, R. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01147-y · Cited by 21
Targetable alterations in invasive pleomorphic lobular carcinoma of the breast
Riedlinger, G., Joshi, S. S., Hirshfield, K. M., Barnard, N., & Ganesan, S. (2021) · Breast Cancer Research · doi:10.1186/s13058-020-01385-5 · Cited by 21
Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1– Mediated Gemcitabine Chemoresistance
Bai, Z., Guo, Z., Liu, J., Chen, Y.-A., Lü, Q., Zhang, P., Hong, L., Wang, Y., & Dong, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.860339 · Cited by 21
Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer
Cao, Y., Li, Y., Liu, R., Zhou, J., & Wang, K. (2023) · Cancers · doi:10.3390/cancers15092568 · Cited by 22
Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer
Christgen, M., Bartels, S., Luft, A., Persing, S., Henkel, D., Lehmann, U., & Kreipe, H. H. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2414-1 · Cited by 21
Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib
Ulaner, G. A., Saura, C., Piha-Paul, S. A., Mayer, I. A., Quinn, D. I., Jhaveri, K. L., Stone, B., Shahin, S., Mann, G., Dujka, M. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1658 · Cited by 21
Self-citation
HER2-targeted multimodal imaging of anaplastic thyroid cancer.
Wei, W., Jiang, D., Rosenkrans, Z. T., Barnhart, T. E., Engle, J. W., Luo, Q., & Cai, W. (2019) · PubMed Central · Cited by 21
Systemic treatment options for advanced biliary tract carcinoma
Xie, C., McGrath, N., Bonilla, C. M., & Fu, J. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01712-9 · Cited by 21
Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib
Shishido, S. N., Masson, R., Xu, L., Welter, L. M., Prabakar, R. K., Souza, A. D., SPICER, D. V., Kang, I. M., Jayachandran, P., Hicks, J. B., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00390-5 · Cited by 21
Mapping actionable pathways and mutations in brain tumours using targeted RNA next generation sequencing
Lenting, K., van den Heuvel, C. N. A. M., van Ewijk, A., Elmelik, D., de Boer, R., Tindall, E. A., Ge, W., Küsters, B., Dorsthorst, M. T., ter Laan, M., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0826-z · Cited by 20
Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2
Riecke, K., & Witzel, I. (2020) · Breast Care · doi:10.1159/000510998 · Cited by 20
Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2- Positive Advanced Solid Tumors Excluding Breast Cancer
Yin, Y., Yang, H., Liu, Z., Tan, J., Zhu, C., Chen, M., Zhou, R., Wang, L., & Qian, J. (2020) · Cancer Management and Research · doi:10.2147/cmar.s281765 · Cited by 20
Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome
Shoucair, S., Habib, J. R., Pu, N., Kinny‐Köster, B., van Oosten, A. F., Javed, A. A., Lafaro, K. J., He, J. P., Wolfgang, C. L., & Yu, J. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11081-z · Cited by 20
HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy
Vathiotis, I. A., Charpidou, A. G., Gavrielatou, N., & Syrigos, K. N. (2021) · Pharmaceuticals · doi:10.3390/ph14121300 · Cited by 20
Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
Campbell, M. R., Ruiz-Sáenz, A., Peterson, E., Agnew, C., Ayaz, P., Garfinkle, S. E., Littlefield, P., Steri, V., Oeffinger, J., Sampang, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110291 · Cited by 20
KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer
Shimozaki, K., Shinozaki, E., Yamamoto, N., Imamura, Y., Osumi, H., Nakayama, I., Wakatsuki, T., Ooki, A., Takahari, D., Ogura, M., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03966-7 · Cited by 20
ERBB3 methylation and immune infiltration in tumor microenvironment of cervical cancer
Yang, X., Chen, Y., Li, M., & Zhu, W. (2022) · Scientific Reports · doi:10.1038/s41598-022-11415-1 · Cited by 20
Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma
Eturi, A., Bhasin, A., Zarrabi, K. K., & Tester, W. J. (2024) · Molecules · doi:10.3390/molecules29081896 · Cited by 20
Sequencing Therapy for Genetically Defined Subgroups of Non–Small Cell Lung Cancer
Yu, H. A., Planchard, D., & Lovly, C. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201331 · Cited by 20
DNA Compatible Intermolecular Wittig Olefination for the Construction of α, β-Unsaturated Carbonyl Compounds
An, Y., Li, K., Shen, Y., Hong, Z., Chen, L., Hu, Y., Zhou, L., Wang, D., Shi, X., Liu, S., et al. (2020) · Organic Letters · doi:10.1021/acs.orglett.0c01215 · Cited by 20
Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses
Huang, C., Tsai, Y., Liu, C., Chao, T., Lien, P., Lin, Y., Feng, C.-J., Chiu, J., Hsu, C., & Tseng, L. (2021) · BMC Cancer · doi:10.1186/s12885-021-07931-4 · Cited by 20
The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
Chilà, G., Guarini, V., Galizia, D., Geuna, E., & Montemurro, F. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s281599 · Cited by 20
Clinicopathologic features and treatment advances in cancers with HER2 alterations
Cen, S., Liu, Z., Pan, H., & Han, W. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188605 · Cited by 20
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier
Jones, L., Cunningham, D., & Starling, N. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102789 · Cited by 20
Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions
Akahane, T., Kanomata, N., Harada, O., Yamashita, T., Kurebayashi, J., Tanimoto, A., & Moriya, T. (2020) · BMC Cancer · doi:10.1186/s12885-020-07432-w · Cited by 19
The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Hu, X., Xu, H., Xue, Q., Wen, R., Jiao, W., & Tian, K. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00387-z · Cited by 19
Direct Observation of Endocytosis Dynamics of Anti-ErbB Modified Single Nanocargoes
Ge, F., Du, Y., & He, Y. (2022) · ACS Nano · doi:10.1021/acsnano.2c00184 · Cited by 19
Detailed curriculum vitae of HER2-targeted therapy
Zhang, X., Gao, Y., Zhang, X.-Y., Guo, N.-J., Hou, W., Wang, S.-W., Zheng, Y., Wang, N., Liu, H., & Wang, B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108417 · Cited by 19
HER2-Altered Non-Small Cell Lung Cancer: A Journey from Current Approaches to Emerging Strategies
Ferrari, G., Rio, B. D., Novello, S., & Passiglia, F. (2024) · Cancers · doi:10.3390/cancers16112018 · Cited by 19
HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China
Zhang, X., Wu, J., Wang, L., Zhao, H., Li, H., Duan, Y., Li, Y., Xu, P. A., Ran, W., & Xing, X. (2020) · PeerJ · doi:10.7717/peerj.8602 · Cited by 19
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer
Nokin, M., Ambrogio, C., Nadal, E., & Santamaría, D. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.11.005 · Cited by 21
Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer
Fang, H., Cavaliere, A., Li, Z., Huang, Y. H., & Marquez-Nostra, B. V. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.627693 · Cited by 19
Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report
Yan, F., Rinn, K. J., Kullnat, J. A., Wu, A., Ennett, M. D., Scott, E. L., & Kaplan, H. G. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7006 · Cited by 19
Tumor mutational landscape is a record of the pre-malignant statePreprint
Kübler, K., Karlić, R., Haradhvala, N. J., Ha, K., Kim, J., Kuzman, M., Jiao, W., Gakkhar, S., Mouw, K. W., Braunstein, L. Z., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/517565 · Cited by 20
Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
Kalra, R., Chen, C. H., Wang, J., Salam, A. B., Dobrolecki, L. E., Lewis, A. N., Sallas, C., Yates, C. C., Gutiérrez, C., Karanam, B., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3106 · Cited by 18
HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma
Bártů, M., Němejcová, K., Michálková, R., Stružinská, I., Hájková, N., Hojny, J., Krkavcová, E., Laco, J., Matěj, R., Drozenová, J., et al. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03640-4 · Cited by 19
TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions
Roviello, G., D’Angelo, A., Sciortino, M., Mini, E., Nobili, S., Logu, F. D., & Massi, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103011 · Cited by 19
Basket trials: From tumour gnostic to tumour agnostic drug development
Dittrich, C. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102082 · Cited by 18
The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality
Tarantino, P., Mazzarella, L., Marra, A., Trapani, D., & Curigliano, G. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102169 · Cited by 18
Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field
Volckmar, A., Christopoulos, P., Kirchner, M., Allgäuer, M., Neumann, O., Budczies, J., Rempel, E., Horak, P., Glade, J., Goldschmid, H., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.022 · Cited by 18
Current status and prospects of targeted therapy for cholangiocarcinoma based on molecular characteristics
Cui, X., Huang, T., Jiang, T., & Wang, H. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217540 · Cited by 18
Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer
Eli, L. D., & Kavuri, S. M. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.48 · Cited by 17
Self-citation
Chinese expert consensus on the diagnosis and treatment of HER2 ‐altered non–small cell lung cancer
Zhang, S., Wang, W., Xu, C., Zhang, Y., Cai, X., Wang, Q., Song, Z., Li, Z., Yu, J., Zhong, W., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14743 · Cited by 17
A Novel Oncogenic Role of FDX1 in Human Melanoma Related to PD-L1 Immune Checkpoint
Lu, H., Liang, J., He, X., Ye, H., Ruan, C., Shao, H., Zhang, R., & Li, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119182 · Cited by 17
Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient’s response to conventional and novel therapies
Liu, L., Wu, M., Huang, A., Gao, C., Yang, Y., Liu, H., Jiang, H., Yu, L., Huang, Y., & Wang, H. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04444-5 · Cited by 17
Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study
Campos, M. A. J., Andújar, I., Keller, F., Mayer, G. J., Rossing, P. R., Staessen, J. A., Delles, C., Beige, J., Glorieux, G., Clark, A. L., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16091298 · Cited by 17
Advances in HER2-Targeted Treatment for Advanced/Metastatic Urothelial Carcinoma
Qu, M., Zhou, L. Q., Yan, X., Li, S., Wu, X., Xu, H., Li, J., Guo, J., Zhang, X., Li, H., et al. (1970) · Bladder · doi:10.14440/bladder.2023.871 · Cited by 17
Landscaping the epigenetic landscape of cancer
Aranda‐Anzaldo, A., & Dent, M. A. R. (2018) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2018.06.005 · Cited by 17
The Role of Predictive Biomarkers in Endocervical Adenocarcinoma: Recommendations From the International Society of Gynecological Pathologists
Bosse, T., Lax, S., Abu‐Rustum, N. R., & Matías‐Guiu, X. (2021) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000755 · Cited by 17
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications
Toss, A., Piacentini, F., Cortesi, L., Artuso, L., Bernardis, I., Parenti, S., Tenedini, E., Ficarra, G., Maiorana, A., Iannone, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25810 · Cited by 17
Integrated genomic characterization of ERBB2/HER2 alterations in invasive breast carcinoma: a focus on unusual FISH groups
Yang, S., Bouhlal, Y., Vega, F. M. D. L., Ballard, M., Kuo, C. J., Vilborg, A., Jensen, G., & Allison, K. H. (2020) · Modern Pathology · doi:10.1038/s41379-020-0504-5 · Cited by 17
A Structural Insight Into Two Important ErbB Receptors (EGFR and HER2) and Their Relevance to Non‐Small Cell Lung Cancer
Topalan, E., Büyükgüngör, A., Çiğdem, M., Gura, S. F., Sever, B., Otsuka, M., Fujita, M., DeMirci, H., & Ciftci, H. I. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202400992 · Cited by 18
Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives
Saito, A., Yoshida, H., Nishikawa, T., & Yonemori, K. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i10.868 · Cited by 17
Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2–Positive Esophagogastric and Gastric Cancer
Hino, K., Nishina, T., Kajiwara, T., Bando, H., Nakamura, M., Kadowaki, S., Minashi, K., Yuki, S., Ohta, T., Hara, H., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00135 · Cited by 17
Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients
Zavarykina, T. M., Lomskova, P., Валерьевна, П. И., Khokhlova, S. V., Stenina, M. B., & Sukhikh, G. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242317073 · Cited by 16
Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development
Lorenzo, S. D., Garajová, I., Stefanini, B., & Tovoli, F. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1928636 · Cited by 16
Targeted Sequencing Revealed Distinct Mutational Profiles of Ocular and Extraocular Sebaceous Carcinomas
Na, H. Y., Park, J. H., Shin, S. A., Lee, S., Lee, H., Chae, H., Choung, H.-K., Kim, N., Chung, J.-H., & Kim, J. E. (2021) · Cancers · doi:10.3390/cancers13194810 · Cited by 16
Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
Yu, I. S., Aubin, F., Goodwin, R. A., Loree, J. M., Mather, C. A., Sheffield, B. S., Snow, S. L., & Gill, S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221111705 · Cited by 17
Molecular alterations and poziotinib efficacy, a pan‐HER inhibitor, in human epidermal growth factor receptor 2 (HER2)‐positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2‐positive breast cancer patients
Kim, J., Lee, E., Park, K., Jung, H. H., Park, W., Lee, K., Sohn, J., Lee, K. S., Jung, K. H., Kim, J. H., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32188 · Cited by 16
The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy
Low, S., & Nakamura, Y. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz073 · Cited by 16
Next-Generation Molecular Imaging of Thyroid Cancer
Jin, Y., Liu, B., Younis, M. H., Huang, G., Liu, J., Cai, W., & Wei, W. (2021) · Cancers · doi:10.3390/cancers13133188 · Cited by 15
Changes in HER3 expression profiles between primary and recurrent gynecological cancers
Kojima, Y., Sudo, K., Yoshida, H., Yazaki, S., Tokura, M., Mizoguchi, C., Okuma, H. S., Kita, S., Yamamoto, K., Nishikawa, T., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-022-02844-z · Cited by 15
Diagnostic Utility of Next-Generation Sequencing in Circulating Free DNA and a Comparison With Matched Tissue in Gallbladder Carcinoma
Mishra, S., Srivastava, P., Pandey, A., Shukla, S., Agarwal, A., & Husain, N. (2023) · Laboratory Investigation · doi:10.1016/j.labinv.2023.100301 · Cited by 15
Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial
Zhou, I., Plana, D., & Palmer, A. C. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0983 · Cited by 15
HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies
Loeffler, E., Ancel, J., Dalstein, V., Deslée, G., Polette, M., & Nawrocki‐Raby, B. (2023) · Life · doi:10.3390/life14010064 · Cited by 15
Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer
Han, B.-Y., Chen, C., Luo, H., Lin, C., Han, X.-C., Nasir, J., Shi, J., Huang, W., Shao, Z., Ling, H., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216763 · Cited by 15
Experimental HER2- targeted therapies for biliary tract cancer
Rizzo, A., Ricci, A. D., Bonucci, C., Tober, N., Palloni, A., Frega, G., & Brandi, G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1854724 · Cited by 15
Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation
Mukohara, T., Hosono, A., Mimaki, S., Nakayama, A., Kusuhara, S., Funasaka, C., Nakao, T., Fukasawa, Y., Kondoh, C. N., Harano, K., et al. (2021) · The Oncologist · doi:10.1002/onco.13715 · Cited by 15
Pyrotinib in HER2 heterogeneously mutated or amplified advanced non-small cell lung cancer patients: a retrospective real-world study (PEARL)
Yang, G., Hao, X., Hu, J., Dong, K., Xu, H., Yang, L., Zhang, S., Yang, Y., Xu, F., Li, J., et al. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.08.001 · Cited by 15
Self-citation
Circular RNA CDK6 suppresses cervical cancer proliferation and metastasis by sponging miR-449a
Zhong, P., Guo, A., Wang, L., Lin, X., & Feng, M. (2022) · Bioengineered · doi:10.1080/21655979.2022.2036898 · Cited by 15
Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer
Yu, H., Xu, Y., Gao, W., Li, M., He, J., Deng, X., & Xing, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.930611 · Cited by 15
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer
Gerratana, L., Davis, A. A., Shah, A. N., Lin, C., Corvaja, C., & Cristofanilli, M. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0667-9 · Cited by 16
Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach
Adesoye, T., Dumbrava, E. E. I., Raghav, K. P. S., Şahin, A. A., Chen, H., Lee, S. S., Javle, M. M., Pant, S., Alhalabi, O., Le, X., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1982 · Cited by 17
Self-citation
Genomics of Breast Cancer Brain Metastases: A Meta-Analysis and Therapeutic Implications
Nguyen, T. T., Hamdan, D., Angeli, E., Feugeas, J., Le, Q. V., Pamoukdjian, F., & Bousquet, G. (2023) · Cancers · doi:10.3390/cancers15061728 · Cited by 15
Predictive and prognostic biomarkers in breast tumours
Krystel‐Whittemore, M., Tan, P. H., & Wen, H. Y. (2023) · Pathology · doi:10.1016/j.pathol.2023.10.014 · Cited by 15
Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer
Zhang, R., Su, C., Jia, Y.-L., Xing, M., Jin, S., & Zong, H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117363 · Cited by 16
Naturally occurring and synthetic constitutive-active cytokine receptors in disease and therapy
Floss, D. M., & Scheller, J. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.05.007 · Cited by 14
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor−positive Metastatic Breast Cancer or Other Solid Tumors
Ballhausen, A., Wheler, J. J., Karp, D. D., Piha-Paul, S. A., Fu, S., Pant, S., Tsimberidou, A. M., Hong, D. S., Subbiah, V., Holley, V. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2878 · Cited by 14
Self-citation
Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy
Rosati, G., Aprile, G., Colombo, A., Cordio, S. S., Giampaglia, M., Cappetta, A., Porretto, C. M., Stefano, A. D., Bilancia, D., & Avallone, A. (2022) · Biomedicines · doi:10.3390/biomedicines10051035 · Cited by 14
Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches
Bontoux, C., Benzaquen, J., Hofman, V., Heeke, S., Hannetel, P., Capela-Brosseau-Laborde, P., Marquette, C., Ilié, M., & Hofman, P. M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101651 · Cited by 14
High Frequency of Juxtamembrane DomainERBB2Mutation in Gastric Cancer
Park, S., Ahn, S., Kim, D. G., Kim, H., Kang, S. Y., & Kim, K. (2021) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20307 · Cited by 14
CHASMplus reveals the scope of somatic missense mutations driving human cancersPreprint
Tokheim, C., & Karchin, R. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/313296 · Cited by 14
Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies
Reinhorn, D. J., Moskovitz, M. T., Tap, W. D., & Li, B. T. (2025) · Cancer · doi:10.1002/cncr.35780 · Cited by 14
Self-citation
The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
Wu, Z., Wang, J., You, F.-M., Li, X., & Xiao, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1142087 · Cited by 13
Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
Malik, P., Rani, R., Solanki, R., Patel, V. H., & Mukherjee, T. K. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00171 · Cited by 14
Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review
Qiang, Z., Wan, J., Chen, X., & Wang, H. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-837 · Cited by 14
Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas
Quaquarini, E., Grillo, F., Gervaso, L., Arpa, G., Fazio, N., Vanoli, A., & Parente, P. (2024) · Cancers · doi:10.3390/cancers16183145 · Cited by 13
Expression of Female Sex Hormone Receptors, Connective Tissue Growth Factor and HER2 in Gallbladder Cancer
Hryciuk, B., Pęksa, R., Bieńkowski, M., Szymanowski, B., Radecka, B. S., Winnik, K., Żok, J., Cichowska, N., Iliszko, M., & Duchnowska, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-58777-y · Cited by 13
Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial
Ai, X., Song, Z., Jian, H., Zhou, Z., Chen, Z., Yu, Y., Li, Z., & Lü, S. (2021) · BMC Cancer · doi:10.1186/s12885-021-08759-8 · Cited by 13
HER2-Targeted Antibody–Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget’s Disease Models: In Vivo and Immunohistochemical Analyses
Tokuchi, K., Maeda, T., Kitamura, S., Yanagi, T., & Ujiie, H. (2022) · Cancers · doi:10.3390/cancers14143519 · Cited by 13
Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
Harada, Y., Sato, A., Nakamura, H., Kai, K., Kitamura, S., Nakamura, T., Kurihara, Y., Ikeda, S., Sueoka, E., Kimura, S. H., et al. (2023) · BMC Cancer · doi:10.1186/s12885-022-10428-3 · Cited by 13
Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination
Rha, S. Y., & Chung, H. C. (2023) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2023.23.e6 · Cited by 14
Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis
Zheng, Y., Shen, G., Zhang, C.-R., Huo, X., Xin, Y., Fang, Q., Guan, Y., Zhao, F., Ren, D., Liu, Z., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01072-7 · Cited by 13
The evolving role of receptors as predictive biomarkers for metastatic breast cancer
Martínez-Pérez, C., Turnbull, A., & Dixon, J. M. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1552138 · Cited by 13
Molecular Pathology of Urothelial Carcinoma
Al‐Ahmadie, H. A., & Netto, G. J. (2021) · Surgical pathology clinics · doi:10.1016/j.path.2021.05.005 · Cited by 14
Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials
Lote, H., & Chau, I. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2030311 · Cited by 13

Authors: Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A. C., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J., Beer, H., Selcuklu, S. D., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler Jr, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J., & Solit, D. B.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
The University of Texas MD Anderson Cancer Center (US)
Vall d'Hebron Hospital Universitari (ES)
Dana-Farber Cancer Institute (US)
USC Norris Comprehensive Cancer Center (US)
Vanderbilt University (US)
Peter MacCallum Cancer Centre (AU)
Washington University in St. Louis (US)
Puma Biotechnology (United States) (US)
Corresponding author: Hyman, David M.
ORCID: Hyman, David M.
Piha-Paul, Sarina A.
Won, Helen
Rodon, Jordi
Saura, Cristina
Shapiro, Geoffrey I.
Juric, Dejan
Quinn, David I.
Mayer, Ingrid A.
Boni, Valentina
Calvo, Emiliano
Loi, Sherene
Lockhart, Albert C.
Erinjeri, Joseph P.
Scaltriti, Maurizio
Ulaner, Gary A.
Patel, Juber
Bouvier, Nancy
Murali, Rajmohan
Schram, Alison M.
Smyth, Lillian M.
Jhaveri, Komal
Li, Bob T.
Drilon, Alexander
Harding, James J.
Iyer, Gopa
Taylor, Barry S.
Berger, Michael F.
Xu, Feng
Eli, Lisa D.
Lalani, Alshad S.
Bryce, Richard P.
Arteaga, Carlos L.
Solit, David B.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2018-01-31
Volume: 554
Issue: 7691
Pages: 189-194
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature25475
PMC: PMC5808581
OpenAlex: W2785610956
Cited by: 780
References: 54
Citations by year: 2026: 40 · 2025: 64 · 2024: 89 · 2023: 99 · 2022: 113 · 2021: 103 · 2020: 113 · 2019: 86 · 2018: 69
FWCI: 34.53
Type: journal article
Language: en
Update notices: correction (2019-02-12)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Minerva Access (University of Melbourne) (submittedVersion)
Funders: Puma Biotechnology
National Institutes of Health (UL1TR000371)
National Cancer Institute (R01CA204749, U01CA180964, R01CA080195, P50CA098131, P30CA008748, P30CA016672, T32CA009207, R25CA020449, P30CA014089)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: HER2 mutation, ERBB2, HER3, neratinib, basket trials, breast cancer, biliary tract cancer, cervical cancer, targeted therapy
MeSH terms: Adult, Aged, Aged, 80 and over, Alleles, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Neoplasms, Quinolines, Cohort Studies, Treatment Outcome, Erb-b2 Receptor Tyrosine Kinases, Mutation, Missense, Receptor, ErbB-3, Protein Kinase Inhibitors, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks